Risk factors

Interest-rate spreads, borrower credit quality, and economic conditions in Bucks, Lehigh, and Montgomery Counties drive core banking risk.

Sound Financial Bancorp's risk profile is dominated by regional economic concentration in Washington state and traditional banking credit risks. Interest rate volatility, liquidity management, and regulatory compliance heavily influence the company's financial results. Emerging risks include artificial intelligence adoption, cybersecurity threats, and climate-related policy shifts.

Silexion is a pre-revenue development-stage biotech company dependent entirely on unproven RNA interference technology for oncology. Operations face extreme regulatory hurdles, intense competition, patent dependencies, and the need for significant capital and personnel.

Operating history is characterized by losses, including $4,760,238 in 2024, and accumulated deficits of $47,639,894. Revenues are vulnerable to supply chain issues, plant relocation, and a small customer base. Dependence on short-term related party notes from directors creates liquidity pressure.

Cash runway extends only into the first quarter of 2026, creating a going concern risk.

Trevi Therapeutics faces significant ongoing net losses, with an accumulated deficit of $287.0 million as of December 31, 2024. The company depends entirely on the clinical success and commercialization of its sole lead product candidate, Haduvio. Financial runway is projected to extend only into the second half of 2026.

One major customer generated 84.9% of 2024 consolidated revenue.

Xenetic Biosciences is heavily dependent on cash of $6.2 million and external financing to fund operations.

XBiotech faces high concentration risk around CEO John Simard, its pipeline, and milestone payments from the Janssen Transaction for Bermekimab.

Exicure faces severe going concern doubts, limited cash, and a lack of active revenue while exploring strategic alternatives.

Revenue depends heavily on repeat customers, annual subscriptions, and continued access to third-party content.

Acacia Research faces significant reliance on its principal stockholder Starboard for sourcing and evaluating acquisition opportunities. The company operates in volatile energy markets through its Benchmark subsidiary, exposing cash flows to commodity price fluctuations. Intellectual property enforcement and patent-related legal expenses present substantial uncertainties and ongoing financial risks.